Moreover, previous studies performed in type 1 and 2 diabetic mice showed that treatment with antibodies against TGF-β1 prevented glomerulosclerosis and interstitial fibrosis, thus supporting a critical role for TGF-β1 signalling in the ECM accumulation characterizing diabetic nephropathy. Here, TGFB1 is linked to diabetic kidney disease.